Global Leukemia Therapeutics Market, By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

April 2021 | 115 pages | ID: GB5B9E002001EN
TechSci Research

Abstracts

Global leukemia therapeutics market was valued USD18584.23 Million in 2020 and is expected to grow at a CAGR of 7.47% during the forecast period. The global leukemia therapeutics market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Supportive government initiatives and policies for promoting cancer awareness are anticipated to fuel the market growth until 2026.

Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning.

The global leukemia therapeutics market can be segmented based on type, gender, age groups, diagnosis, treatment, drugs, route of administration, company and region. Based on type, the market can be bifurcated into chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and others. The chronic lymphocytic leukemia segment led the market in 2020 with share of 34.52%. This can be accredited to the rising geriatric population and increasing funding for research and the development of new cancer therapies. The male and geriatric population are mostly affected by leukemia. The most common diagnosis method of this type of cancer is biopsy whereas, imaging is expected to grow in the near future owing to the improvement and adoption of technology across the globe. Amongst the drug segment, tyrosine kinase inhibitors dominated the global leukemia therapeutic market owing to their greater efficacy and fewer side effects as compared to the rest. Most of the treatments and drugs are administered via injections via intravenous, subcutaneous, intramuscular and intrathecal modes.

Regionally, the leukemia therapeutics market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market with one-third share during the forecast period. This can be attributed to the presence of a large geriatric population base. Besides, the presence of key players in the region is further expected to propel the market over 2026.

Major players operating in the global leukemia therapeutics market include Novartis AG, AbbVie Inc., Roche Holding AG, Amgen Inc., AstraZeneca PLC, Pfizer Inc., Merck & Company Inc., Eli Lilly and Company Ltd., Bristol-Myers Squibb Company, Gilead Sciences Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Stemline Therapeutics Inc., iCell Gene Therapeutics, Otsuka Holdings Company Ltd. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in September 2020, Gilead Sciences Inc. completed the acquisition of Immunomedics Inc., which was one of the biggest acquisition in 2020.

Years considered for this report:

• Historical Years: 2016-2019
• Base Year: 2020
• Estimated Year: 2021
• Forecast Period: 2022– 2026

Objective of the Study:

• To analyze historical growth in market size of global leukemia therapeutics market from 2016 to 2020.
• . To estimate and forecast the market size of global leukemia therapeutics market from 2021 to 2026 and growth rate until 2026.
• To classify and forecast global leukemia therapeutics market based on factor, severity, blood cell, age groups, gender, treatment, diagnosis, route of administration, drugs, company and regional distribution.
• To identify drivers and challenges for global leukemia therapeutics market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global leukemia therapeutics market.
• To identify and analyze the profiles of leading players operating in global leukemia therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global leukemia therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Leukemia drugs manufacturers, suppliers, distributors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to leukemia therapeutics
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global leukemia therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Global Leukemia Therapeutics Market, By Type:
• Chronic Lymphocytic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Acute Lymphocytic Leukemia
• Others
• Global Leukemia Therapeutics Market, By Gender:
• Male
• Female
• Global Leukemia Therapeutics Market, By Age Groups:
• 0-15
• 15-30
• 30-50
• 50+
• Global Leukemia Therapeutics Market, By Diagnosis:
• Blood test
• Biopsy
• Physical Exam
• Imaging
• Global Leukemia Therapeutics Market, By Treatment:
• Chemotherapy
• Stem Cell Transplantation
• Immunotherapy
• Targeted Therapy
• Others
• Global Leukemia Therapeutics Market, By Drugs:
• Tyrosine Kinase Inhibitors
• Antimetabolites
• Hormones (Corticosteroids)
• Monoclonal Antibodies
• Others
• Global Leukemia Therapeutics Market, By Route of Administration:
• Oral
• Parenteral
• Global Leukemia Therapeutics Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• South America
• Brazil
• Argentina
• Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global leukemia therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON GLOBAL LEUKEMIA THERAPEUTICS MARKET

4. EXECUTIVE SUMMARY

5. VOICE OF CUSTOMER

5.1. Brand Awareness
5.2. Factors driving Global Leukemic Therapeutics Market
5.3. Unmet Needs and Challenges

6. GLOBAL LEUKEMIA THERAPEUTICS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others)
  6.2.2. By Gender (Male, Female)
  6.2.3. By Age Groups (0-15, 15-30, 30-50, 50+)
  6.2.4. By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging)
  6.2.5. By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others)
  6.2.6. By Drugs (Antimetabolites, Hormones (Corticosteroids), Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others)
  6.2.7. By Route of Administration (Oral, Parenteral)
  6.2.8. By Company (2020)
  6.2.9. By Region

7. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Type
  7.2.2. By Diagnosis
  7.2.3. By Treatment
  7.2.4. By Drugs
  7.2.5. By Route of Administration
  7.2.6. By Country
7.3. North America: Country Analysis
  7.3.1. United States Leukemia Therapeutics Market Outlook
  7.3.1.1. Market Size & Forecast
  7.3.1.1.1. By Value
  7.3.1.2. Market Share & Forecast
  7.3.1.2.1. By Type
  7.3.1.2.2. By Diagnosis
  7.3.1.2.3. By Treatment
  7.3.1.2.4. By Drugs
  7.3.1.2.5. By Route of Administration
  7.3.2. Canada Leukemia Therapeutics Market Outlook
  7.3.2.1. Market Size & Forecast
  7.3.2.1.1. By Value
  7.3.2.2. Market Share & Forecast
  7.3.2.2.1. By Type
  7.3.2.2.2. By Diagnosis
  7.3.2.2.3. By Treatment
  7.3.2.2.4. By Drugs
  7.3.2.2.5. By Route of Administration
  7.3.3. Mexico Leukemia Therapeutics Market Outlook
  7.3.3.1. Market Size & Forecast
  7.3.3.1.1. By Value
  7.3.3.2. Market Share & Forecast
  7.3.3.2.1. By Type
  7.3.3.2.2. By Diagnosis
  7.3.3.2.3. By Treatment
  7.3.3.2.4. By Drugs
  7.3.3.2.5. By Route of Administration

8. EUROPE LEUKEMIA THERAPEUTICS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Type
  8.2.2. By Diagnosis
  8.2.3. By Treatment
  8.2.4. By Drugs
  8.2.5. By Route of Administration
  8.2.6. By Country
8.3. Europe: Country Analysis
  8.3.1. Germany Leukemia Therapeutics Market Outlook
  8.3.1.1. Market Size & Forecast
  8.3.1.1.1. By Value
  8.3.1.2. Market Share & Forecast
  8.3.1.2.1. By Type
  8.3.1.2.2. By Diagnosis
  8.3.1.2.3. By Treatment
  8.3.1.2.4. By Drugs
  8.3.1.2.5. By Route of Administration
  8.3.2. France Leukemia Therapeutics Market Outlook
  8.3.2.1. Market Size & Forecast
  8.3.2.1.1. By Value
  8.3.2.2. Market Share & Forecast
  8.3.2.2.1. By Type
  8.3.2.2.2. By Diagnosis
  8.3.2.2.3. By Treatment
  8.3.2.2.4. By Drugs
  8.3.2.2.5. By Route of Administration
  8.3.3. United Kingdom Leukemia Therapeutics Market Outlook
  8.3.3.1. Market Size & Forecast
  8.3.3.1.1. By Value
  8.3.3.2. Market Share & Forecast
  8.3.3.2.1. By Type
  8.3.3.2.2. By Diagnosis
  8.3.3.2.3. By Treatment
  8.3.3.2.4. By Drugs
  8.3.3.2.5. By Route of Administration
  8.3.4. Italy Leukemia Therapeutics Market Outlook
  8.3.4.1. Market Size & Forecast
  8.3.4.1.1. By Value
  8.3.4.2. Market Share & Forecast
  8.3.4.2.1. By Type
  8.3.4.2.2. By Diagnosis
  8.3.4.2.3. By Treatment
  8.3.4.2.4. By Drugs
  8.3.4.2.5. By Route of Administration
  8.3.5. Spain Leukemia Therapeutics Market Outlook
  8.3.5.1. Market Size & Forecast
  8.3.5.1.1. By Value
  8.3.5.2. Market Share & Forecast
  8.3.5.2.1. By Type
  8.3.5.2.2. By Diagnosis
  8.3.5.2.3. By Treatment
  8.3.5.2.4. By Drugs
  8.3.5.2.5. By Route of Administration

9. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Type
  9.2.2. By Diagnosis
  9.2.3. By Treatment
  9.2.4. By Drugs
  9.2.5. By Route of Administration
  9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
  9.3.1. China Leukemia Therapeutics Market Outlook
  9.3.1.1. Market Size & Forecast
  9.3.1.1.1. By Value
  9.3.1.2. Market Share & Forecast
  9.3.1.2.1. By Type
  9.3.1.2.2. By Diagnosis
  9.3.1.2.3. By Treatment
  9.3.1.2.4. By Drugs
  9.3.1.2.5. By Route of Administration
  9.3.2. India Leukemia Therapeutics Market Outlook
  9.3.2.1. Market Size & Forecast
  9.3.2.1.1. By Value
  9.3.2.2. Market Share & Forecast
  9.3.2.2.1. By Type
  9.3.2.2.2. By Diagnosis
  9.3.2.2.3. By Treatment
  9.3.2.2.4. By Drugs
  9.3.2.2.5. By Route of Administration
  9.3.3. Japan Leukemia Therapeutics Market Outlook
  9.3.3.1. Market Size & Forecast
  9.3.3.1.1. By Value
  9.3.3.2. Market Share & Forecast
  9.3.3.2.1. By Type
  9.3.3.2.2. By Diagnosis
  9.3.3.2.3. By Treatment
  9.3.3.2.4. By Drugs
  9.3.3.2.5. By Route of Administration
  9.3.4. South Korea Leukemia Therapeutics Market Outlook
  9.3.4.1. Market Size & Forecast
  9.3.4.1.1. By Value
  9.3.4.2. Market Share & Forecast
  9.3.4.2.1. By Type
  9.3.4.2.2. By Diagnosis
  9.3.4.2.3. By Treatment
  9.3.4.2.4. By Drugs
  9.3.4.2.5. By Route of Administration
  9.3.5. Australia Leukemia Therapeutics Market Outlook
  9.3.5.1. Market Size & Forecast
  9.3.5.1.1. By Value
  9.3.5.2. Market Share & Forecast
  9.3.5.2.1. By Type
  9.3.5.2.2. By Diagnosis
  9.3.5.2.3. By Treatment
  9.3.5.2.4. By Drugs
  9.3.5.2.5. By Route of Administration

10. SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Type
  10.2.2. By Diagnosis
  10.2.3. By Treatment
  10.2.4. By Drugs
  10.2.5. By Route of Administration
  10.2.6. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Leukemia Therapeutics Market Outlook
  10.3.1.1. Market Size & Forecast
  10.3.1.1.1. By Value
  10.3.1.2. Market Share & Forecast
  10.3.1.2.1. By Type
  10.3.1.2.2. By Diagnosis
  10.3.1.2.3. By Treatment
  10.3.1.2.4. By Drugs
  10.3.1.2.5. By Route of Administration
  10.3.2. Argentina Leukemia Therapeutics Market Outlook
  10.3.2.1. Market Size & Forecast
  10.3.2.1.1. By Value
  10.3.2.2. Market Share & Forecast
  10.3.2.2.1. By Type
  10.3.2.2.2. By Diagnosis
  10.3.2.2.3. By Treatment
  10.3.2.2.4. By Drugs
  10.3.2.2.5. By Route of Administration
  10.3.3. Colombia Leukemia Therapeutics Market Outlook
  10.3.3.1. Market Size & Forecast
  10.3.3.1.1. By Value
  10.3.3.2. Market Share & Forecast
  10.3.3.2.1. By Type
  10.3.3.2.2. By Diagnosis
  10.3.3.2.3. By Treatment
  10.3.3.2.4. By Drugs
  10.3.3.2.5. By Route of Administration

11. MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Type
  11.2.2. By Diagnosis
  11.2.3. By Treatment
  11.2.4. By Drugs
  11.2.5. By Route of Administration
  11.2.6. By Country
11.3. MEA: Country Analysis
  11.3.1. South Africa Leukemia Therapeutics Market Outlook
  11.3.1.1. Market Size & Forecast
  11.3.1.1.1. By Value
  11.3.1.2. Market Share & Forecast
  11.3.1.2.1. By Type
  11.3.1.2.2. By Diagnosis
  11.3.1.2.3. By Treatment
  11.3.1.2.4. By Drugs
  11.3.1.2.5. By Route of Administration
  11.3.2. Saudi Arabia Leukemia Therapeutics Market Outlook
  11.3.2.1. Market Size & Forecast
  11.3.2.1.1. By Value
  11.3.2.2. Market Share & Forecast
  11.3.2.2.1. By Type
  11.3.2.2.2. By Diagnosis
  11.3.2.2.3. By Treatment
  11.3.2.2.4. By Drugs
  11.3.2.2.5. By Route of Administration
  11.3.3. UAE Leukemia Therapeutics Market Outlook
  11.3.3.1. Market Size & Forecast
  11.3.3.1.1. By Value
  11.3.3.2. Market Share & Forecast
  11.3.3.2.1. By Type
  11.3.3.2.2. By Diagnosis
  11.3.3.2.3. By Treatment
  11.3.3.2.4. By Drugs
  11.3.3.2.5. By Route of Administration

12. MARKET DYNAMICS

12.1. Drivers
12.2. Challenges

13. MARKET TRENDS & DEVELOPMENTS

14. CLINICAL TRIAL ANALYSIS

15. COMPETITIVE LANDSCAPE

15.1. Competition Outlook
15.2. Players Profiled (Leading Companies)
  15.2.1. Novartis AG
  15.2.2. AbbVie Inc.
  15.2.3. Roche Holding AG
  15.2.4. Amgen Inc.
  15.2.5. AstraZeneca PLC
  15.2.6. Pfizer Inc.
  15.2.7. Merck & Company Inc.
  15.2.8. Eli Lilly and Company Ltd.
  15.2.9. Bristol-Myers Squibb Company
  15.2.10. Gilead Sciences Inc.
  15.2.11. Astellas Pharma Inc.
  15.2.12. Takeda Pharmaceutical Company Ltd.
  15.2.13. Stemline Therapeutics Inc.
  15.2.14. iCell Gene therapeutics
  15.2.15. Otsuka Holdings Company Ltd.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

List Of Figures

LIST OF FIGURES

Figure 1: Global Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 2: Global Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 3: Global Leukemia Therapeutics Market Share, By Gender, 2016-2026F
Figure 4: Global Leukemia Therapeutics Market Share, By Age Groups, 2016-2026F
Figure 5: Global Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 6: Global Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 7: Global Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 8: Global Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 9: Global Leukemia Therapeutics Market, Market Map, By Region, By Value, 2016-2026F
Figure 10: North America Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 11: North America Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 12: North America Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 13: North America Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 14: North America Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 15: North America Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 16: North America Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 17: United States Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 18: United States Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 19: United States Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 20: United States Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 21: United States Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 22: United States Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 23: Canada Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 24: Canada Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 25: Canada Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 26: Canada Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 27: Canada Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 28: Canada Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 29: Mexico Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 30: Mexico Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 31: Mexico Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 32: Mexico Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 33: Mexico Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 34: Mexico Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 35: Europe Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 36: Europe Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 37: Europe Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 38: Europe Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 39: Europe Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 40: Europe Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 41: Europe Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 42: Germany Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 43: Germany Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 44: Germany Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 45: Germany Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 46: Germany Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 47: Germany Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 48: France Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 49: France Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 50: France Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 51: France Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 52: France Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 53: France Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 54: United Kingdom Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 55: United Kingdom Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 56: United Kingdom Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 57: United Kingdom Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 58: United Kingdom Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 59: United Kingdom Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 60: Italy Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 61: Italy Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 62: Italy Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 63: Italy Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 64: Italy Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 65: Italy Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 66: Spain Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 67: Spain Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 68: Spain Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 69: Spain Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 70: Spain Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 71: Spain Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 72: Asia-Pacific Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 73: Asia-Pacific Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 74: Asia-Pacific Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 75: Asia-Pacific Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 76: Asia-Pacific Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 77: Asia-Pacific Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 78: Asia-Pacific Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 79: China Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 80: China Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 81: China Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 82: China Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 83: China Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 84: China Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 85: India Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 86: India Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 87: India Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 88: India Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 89: India Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 90: India Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 91: Japan Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 92: Japan Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 93: Japan Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 94: Japan Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 95: Japan Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 96: Japan Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 97: South Korea Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 98: South Korea Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 99: South Korea Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 100: South Korea Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 101: South Korea Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 102: South Korea Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 103: Australia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 104: Australia Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 105: Australia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 106: Australia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 107: Australia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 108: Australia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 109: South America Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 110: South America Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 111: South America Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 112: South America Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 113: South America Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 114: South America Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 115: South America Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 116: Brazil Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 117: Brazil Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 118: Brazil Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 119: Brazil Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 120: Brazil Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 121: Brazil Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 122: Argentina Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 123: Argentina Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 124: Argentina Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 125: Argentina Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 126: Argentina Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 127: Argentina Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 128: Colombia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 129: Colombia Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 130: Colombia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 131: Colombia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 132: Colombia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 133: Colombia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 134: Middle East and Africa Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 135: Middle East and Africa Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 136: Middle East and Africa Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 137: Middle East and Africa Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 138: Middle East and Africa Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 139: Middle East and Africa Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 140: Middle East and Africa Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 141: South Africa Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 142: South Africa Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 143: South Africa Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 144: South Africa Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 145: South Africa Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 146: South Africa Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 147: Saudi Arabia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 148: Saudi Arabia Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 149: Saudi Arabia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 150: Saudi Arabia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 151: Saudi Arabia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 152: Saudi Arabia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 153: UAE Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 154: UAE Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 155: UAE Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 156: UAE Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 157: UAE Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 158: UAE Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F